文献速递头颈外科

治疗前低骨骼肌质量与头颈癌顺铂放化疗剂量限制性毒性的关联

The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin.
PubMed 文献 · Head Neck · 2021-10-29

结果显示低骨骼肌质量与顺铂剂量限制性毒性独立相关(OR 3.99)。常规骨骼肌评估可能有助于毒性风险分层与治疗优化。

要点

  • 治疗前低骨骼肌质量是顺铂剂量限制性毒性的独立预测因素。
  • 低骨骼肌质量患者剂量限制性毒性发生率显著高于正常骨骼肌质量者。
  • eGFR 60-70 ml/min同样与剂量限制性毒性风险升高相关。

核心结论

  • 在局部晚期头颈鳞癌接受大剂量顺铂根治性放化疗的患者中,治疗前低骨骼肌质量与化疗剂量限制性毒性相关。
  • 常规骨骼肌质量评估可能有助于评估剂量限制性毒性风险并优化治疗。

研究设计与样本

  • 回顾性纳入连续接受大剂量顺铂根治性放化疗的局部晚期头颈鳞癌患者。
  • 累计顺铂剂量低于200 mg/m2定义为化疗剂量限制性毒性。

主要发现

  • 37例(24.2%)发生化疗剂量限制性毒性,84例(54.9%)存在低骨骼肌质量。
  • 低骨骼肌质量患者化疗剂量限制性毒性发生率高于正常骨骼肌质量患者(35.7% vs. 10.1%,p < 0.01)。
  • 低骨骼肌质量是化疗剂量限制性毒性的预测因素(OR 3.99 [95% CI 1.56-10.23],p = 0.01)。
  • eGFR 60-70 ml/min也是化疗剂量限制性毒性的预测因素(OR 5.40 [95% CI 1.57-18.65],p < 0.01)。

关键数值与推荐

  • 低骨骼肌质量判定基于治疗前CT影像测量。
  • 化疗剂量限制性毒性定义为累计顺铂剂量低于200 mg/m2。

临床怎么用

  • 对局部晚期头颈鳞癌拟行大剂量顺铂放化疗的患者,可考虑治疗前CT评估骨骼肌质量以辅助毒性风险分层。
  • 低骨骼肌质量或eGFR 60-70 ml/min的患者可能需要更密切的毒性监测与个体化治疗调整。

局限性

  • 本研究为回顾性设计,样本来自单中心连续病例,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose-limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM is a predictor for CDLT. We aimed to validate these findings. METHODS: Consecutive LA-HNSCC patients treated with primary CRT with high-dose cisplatin were retrospectively included. SMM was measured on pre-treatment CT-imaging. A cumulative cisplatin dose below 200 mg/m2 was defined as CDLT. RESULTS: One hundred and fifty three patients were included; 37 (24.2%) experienced CDLT, and 84 had low SMM (54.9%). Patients with low SMM experienced more CDLT than patients with normal SMM (35.7% vs. 10.1%, p < 0.01). Low SMM (OR 3.99 [95% CI 1.56-10.23], p = 0.01) and an eGFR of 60-70 ml/min (OR 5.40 [95% CI 1.57-18.65], p < 0.01) were predictors for CDLT. CONCLUSION: Pre-treatment low SMM is associated with CDLT in LA-HNSCC patients treated with primary CRT. Routine SMM assessment may allow for CDLT risk assessment and treatment optimization.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Bril SI, Al-Mamgani A, Chargi N, et al. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. Head Neck. 2021. PMID: 34713519. doi:10.1002/hed.26919

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。